Physician profile
John D Hixson
NPI 1336130475
$191,064.06
in general payments reported to CMS, 2019-2025
13 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $186K · 2021: $526 · 2022: $825 · 2023: $559 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,985 · Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,985.00 |
| Food and Beverage | $131.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $175,000.00 | 2020 | |
| Sunovion Pharmaceuticals INC. | $5,862.00 | 2020 | |
| Livanova USA, INC. | $4,762.03 | 2020-2021 | |
| Servier Pharmaceuticals LLC | $2,557.20 | 2025 | |
| Biogen, INC. | $1,389.90 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $500.00 | 2023 | |
| Amgen INC. | $433.31 | 2019 | |
| Greenwich Biosciences, INC. | $142.13 | 2019 | |
| Ucb, INC. | $128.79 | 2019 | |
| Novocure INC. | $116.44 | 2021 | |
| Gilead Sciences, INC. | $58.92 | 2023 | Trodelvy |
| Neuropace, INC. | $56.67 | 2019 | |
| Zimmer Biomet Holdings, INC. | $56.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hixson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.